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INTRODUCTION
The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) banned the use of
differential rules in the provision of mental health care. In an effort to combat discrimination
in health insurance against those suffering from mental health conditions, this federal mandate
called for large-group employer health insurance plans that cover mental health benefits to provide
equivalent coverage for mental health and physical health treatments (1). The parity law did
not apply to individual and small-group plans; however, this gap was addressed in the Patient
Protection and Affordable Care Act (PPACA or “ACA”). The new act not only required that
individual and small-group plans treat behavioral health services with parity, but it also established
behavioral health as one of the “essential benefits” required to be offered in the Marketplace
plans that were established through the ACA (2). A primary ethical imperative undergirding such
legislation is the intersection of the core principles of beneficence, non-malevolence, and justice,
wherein moral responsibilities dictate safe and sound clinical intervention (s), which avoid harm,
to be equitably provided to those in need. Ethico-legal constructs of non-discrimination and fair
access to health care further support these obligations. Yet, despite such ethical and legislative
imperatives, there remains a considerable discrepancy between the law and the application of
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(FDA) approved humanitarian device exemption (HDE) (13),
insurers commonly refuse to provide reimbursement for this
intervention. There are two fundamental problems with the
positions that many insurers have taken with regard to this
important service. First, they are wrong in concluding that
DBS therapy for treatment-resistant OCD should be excluded
under applicable health insurance plans as experimental and
investigational. In fact, such a position is demonstrably false. The
HDE granted by the U.S. FDA (HDE #H050003) on February
19, 2009 (13) provides explicit affirmation that “the probable
benefit to health from use of the device outweighs the risk
of injury or illness from its use while taking into account the
probable risks and benefits of currently available devices or
alternative forms of treatment” (14). Investigational devices are
covered by Investigational Device Exemptions (IDEs), rather
than HDEs (15).
Second, excluding coverage for DBS therapy for OCD is a clear
parity violation in light of the fact that major health insurers
routinely provide coverage for the use of DBS in the treatment
of dystonia, a movement disorder in which a person’s muscles
contract in a sustained and uncontrollable fashion. Notably, DBS
for the treatment of dystonia, which is supported by similar
levels of evidence as DBS for OCD (16), is also FDA-approved
under an HDE (HDE #020007) (17). The medical policies used
by most insurers classify DBS for dystonia, a movement disorder,
as medically necessary. For example, since 2005, surgeons at
University of Colorado have performed 39 DBS surgeries for
dystonia with no denials of coverage. Since 2015, surgeons at
University of Colorado have performed 7 DBS surgeries for OCD.
Three were covered by Medicare and three by Medicaid. One
was denied by private insurance, but the denial was overturned
at external review. Coverage for an 8th potential candidate was
denied by a private insurer. A 9th patient of the first author had
surgery at an outside hospital, and the hospital wrote off charges
as charity as well as the family payed out-of-pocket when the
claims were denied by a private insurer. Reasons the author have
encountered for denial of authorization of DBS for OCD include
variations of “experimental and investigational:”

benefits to persons suffering from mental health conditions. It is
therefore critical that legal and advocacy groups coordinate their
efforts to ensure that behavioral health services for those in need
are provided and covered by insurance.

WIT V. UNITED BEHAVIORAL HEALTH
On March 5, 2019, the United States District Court for the
Northern District of California in Wit v. United Behavioral
Health found that United Behavioral Health (“UBH”) breached
its fiduciary duties to its insureds under the Employee Retirement
Income Security Act (ERISA) by relying upon flawed medical
necessity criteria to deny coverage for more than 67,000
claims for treatment of mental and substance use disorders
over a period of many years. Specifically, the court found
that UBH prioritized its own financial interests above the
needs of its insureds by failing to utilize medical necessity
criteria that were consistent with generally accepted standards
of care (3, 4). While the Wit case did not directly assert a
parity act violation, which would have required comparing the
behavioral guidelines to those used by United Healthcare for
medical/surgical services, the Wit case’s focus on the restrictive
coverage policies America’s largest insurer used to justify the
denial of thousands of behavioral health claims highlights
the need for more aggressive oversight of insurers to ensure
the provision of appropriate coverage and challenge improper
denials of behavioral health claims. This decision may be a
watershed moment in the effort to force accountability on
insurance companies making coverage decisions relating to
behavioral health services. Indeed, former U.S. Representative
Patrick Kennedy, the original sponsor of MHPAEA, declared
that the “breathtaking” Wit ruling was “the Brown v. Board of
Education for the mental health movement (5).” Considering
this landmark decision, other relevant case law (6), ethical
obligations, and our collective experience of repeated restriction
of access to appropriate mental health treatment for obsessivecompulsive disorder (OCD), the authors of this opinion article
felt compelled to act. We therefore convened a multidisciplinary
group of experts in the field of neuromodulation for psychiatric
disorders, including neurosurgeons, neurologists, psychiatrists,
psychologists, a neuroethicist, and attorneys with expertise in
insurance law (including one of the primary attorneys involved
in the Wit case). Following extensive discussion, we collectively
argue for a change in the coverage of mental health services
related to psychiatric neuromodulation.

• . . . investigational and not medically necessary
• . . . your plan does not cover services that are investigational,
meaning there is insufficient evidence to support the efficacy
of the treatment compared to standard means of treatment
or diagnosis.
• . . . this service is not considered medically necessary for your
condition (obsessive-compulsive disorder) because the plan
policy and literature to not support this procedure for your
diagnosis as standard of care.
• . . . your health plan guidelines. . . show that this type of surgery
is unproven because there is not enough evidence that it is
effective. It is not medically necessary.
• There are not enough studies to show the device will help your
problem. There are not enough studies to show the device is
better than other regular treatment for your problem.
• Plan does not cover investigational.
• FDA approval does not obligate us to cover the surgery. We
consider it unproven in terms of efficacy.

DBS FOR OCD AND MENTAL HEALTH
PARITY LAWS
This opinion article is posed as a challenge to the unacceptably
common stance of insurers to deny coverage for deep brain
stimulation (DBS) for the treatment of severe and intractable
OCD (7, 8). Despite the promulgation of generally accepted
standards of care for the use of DBS in individuals with severe,
disabling, treatment-refractory OCD (9–12), and regulatory
approval of DBS via a U.S. Food and Drug Administration
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None of the authors found record of an authorization of DBS for
OCD that was denied based on true medical necessity criteria, i.e.,
the chronicity, refractoriness, and severity of a patient’s illness.
There is simply no rational basis to find DBS therapy for OCD
to be experimental and investigational, while covering its use
for dystonia, given that the status of research and government
approval for these two indications is comparable. In fact, the only
difference is OCD is a mental health condition, while dystonia
is a medical condition affecting motor control. Under the dense
terminology of MHPAEA’s implementing rules, this appears to
be an instance of insurers considering and applying “evidentiary
standards” more stringently to mental health benefits than
to medical benefits (18). Such practice can—and should—be
regarded as discriminatory.
OCD is a debilitating psychiatric condition that occurs in 2.3%
of the U.S. population (19). Individuals with OCD experience
reduced quality of life, with impairment in multiple domains, and
OCD is a chronic condition for most (20–22). Standard-of-care
treatment for OCD is exposure and response prevention (ERP),
either alone or in combination with serotonergic medication(s).
Even with optimal treatment, however, only about 35% of
individuals with OCD achieve remission (defined as a YaleBrown Obsessive Compulsive Scale [Y-BOCS] score of ≤7)
(23), and 10–20% remain severely affected (24). DBS is a
highly effective treatment option for this group of severe,
treatment-refractory patients. Several clinical trials, including
some with randomized double-blind sham-controlled designs,
have demonstrated positive response rates to DBS (defined
as ≥35% YBOCS reduction) in 50–70% of patients (25–29).
This success rate is significant given the treatment-refractory
nature of these patients. A 2014 systematic review and evidencebased guidelines, conducted and formulated by the American
Society for Stereotactic and Functional Neurosurgery (ASSFN)
and the Congress of Neurological Surgeons (CNS) (9), as well
as a recent update of these guidelines (30), all detail the
high level of scientific evidence supporting the use of DBS
for treatment-resistant OCD. Treatment guidelines authored
by the American Psychiatric Association and the Anxiety and
Depression Association of America also recommend the option
of DBS for treatment-refractory OCD, if performed at an
institution with expertise in both OCD and neuromodulatory
surgery (31, 32).
Still, insurers persist in denying coverage for this effective
treatment, forcing families, clinicians, and institutions to expend
significant time and resources pursuing appeals for authorization
of services. Such efforts are rarely successful and frequently
cannot even be undertaken, due in large part, to a lack of
resources and low resilience among individuals suffering from
debilitating illness. A recent review identified private insurance
denials as the most frequent factor underlying an appropriate
candidate’s inability to proceed with DBS surgery (7). Appeal
panels and “independent” reviews are often staffed by physicians
who lack expertise in neurosurgery or OCD, let alone insight
into the use, viability, and value of neuromodulatory surgery
for psychiatric disorders. Given the associated costs, the result
is that most people who need DBS as the last and best hope for
recovery from severely debilitating OCD are unable to obtain it.
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As one California court noted, an improper denial “following
retrospective review will result in the wrongful withholding of
payment” while “[a]n erroneous decision in a prospective review”
leads to “the withholding of necessary care, potentially leading
to a patient’s permanent disability or death (33).” This scenario
is precisely what occurs when insurers refuse to authorize
this medically essential treatment, forcing patients to continue
suffering through an otherwise untreatable condition with high
potential for long-term disability. Equally alarming are instances
in which insurers refuse reimbursement of services rendered,
even after they have been pre-authorized (8). This state of affairs
imposes ever-increasing burdens on those with mental illness and
the healthcare teams caring for them.

GENERALLY ACCEPTED STANDARDS OF
CARE
The medical necessity criteria for the use of DBS for the treatment
of refractory OCD are well-established and accepted by experts in
the field of neuromodulation for psychiatric disorders. Medical
necessity is based on a determination by the treating psychiatrist’s
assessment of disability, severity, chronicity, and refractoriness of
the illness. These criteria, which have been established based on
empirical data, reflect the generally accepted standards of care.
We outline these criteria in Table 1 (12, 25, 28, 32, 35–37).
In 2002, to prevent misuses, the OCD-DBS Collaborative
Group outlined an ethical framework for performing DBS for
OCD (11, 38). The evaluation of individuals and administration
of DBS for OCD should be implemented by a multi-disciplinary
team, including a stereotactic and functional neurosurgeon, a
psychiatrist, an OCD expert therapist, and a neuropsychologist.
Individuals must have a thorough psychiatric evaluation, which
includes suicide risk assessment, by a psychiatrist who is
an expert in the treatment of OCD. Potential candidates
for DBS must undergo formal neuropsychological assessment,
including cognitive testing, psychiatric interview, evaluation of
interpersonal functioning, and discussion of expectations for
surgery. Comorbidities must be carefully evaluated and treated
before and throughout the process (39, 40). In the United States,
institutions must have the requisite IRB approval supporting the
FDA HDE.
If insurers are to satisfy generally accepted standards of care, as
required by the Wit court, they must adopt guidelines that ensure
coverage of DBS for OCD when these standards have been met
(see Table 1). Their failure to follow such guidelines is inherently
improper, just as were UBH’s overly restrictive internal guidelines
for the provision of behavioral health services.

DISCUSSION
In conclusion, OCD is associated with a high level of disability,
and a small number of individuals have incapacitating illness
that is refractory to conventional treatments. We argue that in
accordance with current ethico-legal standards, these individuals
are eligible for DBS as an option to alleviate their suffering. Extant
outcome data support the validity and value of DBS therapy for
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TABLE 1 | Medical necessity criteria for the use of DBS for refractory OCD*.
Chronicity

OCD Diagnosis for duration of at least 5 years

Severity

Y-BOCS ≥ 28

Functional Impairment

In at least one of the domains of: activities of daily living;
social functioning; occupational functioning; thinking,
concentration, and judgment; or ability to engage in other
major life areas (34)

Treatment-refractoriness

Persistence of severe symptoms (Y-BOCS ≥ 28) despite:

Adequate trials (of at least 12-weeks in duration) of
three serotonergic medications at FDA-maximum approved
dosages or greater (one of which must be clomipramine)
• The requirement for clomipramine may be excluded if the
patient experiences adverse effects, does not tolerate the
drug, or its use is otherwise contraindicated.
The use of adjunctive pharmacological agents including a
long-acting benzodiazepine and an antipsychotic.
• The requirement for a benzodiazepine may be excluded if
the patient has a history of substance use disorder or
another contraindication to benzodiazepines
Engagement in exposure therapy for at least 20 sessions with
a clinician experienced in the treatment of OCD

*Generally accepted standards evolve with time, with gains in medical knowledge and development of new treatment options. These criteria should not be considered static or immutable.

OCD, and the strength of these data have been recognized both
in peer-reviewed guidelines and by the FDA’s HDE mark. Thus,
we opine that in such cases, the potential benefits of DBS therapy
outweigh the risks. The medical policies and practices of insurers
who unjustifiably restrict access to DBS in the OCD population
are inconsistent with healthcare law. These policies prevent fair
access to those individuals most in need, and in denying such
coverage, insurers have failed to remain on par with treatment of
other medical conditions such as dystonia. We find this position
to be both unethical and illegal.

Restriction of Access to Deep Brain Stimulation for Refractory
OCD: Failure to Apply the Federal Parity Act.
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